<DOC>
	<DOCNO>NCT00001335</DOCNO>
	<brief_summary>The prognosis patient metastatic Ewing 's sarcoma family tumor ( ESF ) , rhabdomyosarcoma ( RMS ) , neuroblastoma ( NBL ) remain dismal , less 25 % long-term disease-free survival . Though less grave , prognosis cure high-risk patient approximately 50 % . New treatment strategy , include identification highly active new agent , maximize dose intensity active standard drug , development improve method consolidation eradicate microscopic residual disease , clearly need improve outcome patient . This protocol address issue commence Phase II window , high risk patient , evaluate series promise drug novel mechanism action . All patient receive 5 cycle dose-intensive `` best standard therapy '' doxorubicin ( adriamycin ) , vincristine , cyclophosphamide ( VAdriaC ) . Patients high risk relapse continue onto phase I consolidation regimen consist three cycle dose-escalated Melphalan , Ifosfamide , Mesna , Etoposide ( MIME ) . Peripheral blood stem cell transfusion ( PBSCT ) recombinant human G-CSF use supportive care measure allow maximal dose-escalation combination regimen .</brief_summary>
	<brief_title>New Therapeutic Strategies Patients With Ewing 's Sarcoma Family Tumors , High Risk Rhabdomyosarcoma , Neuroblastoma</brief_title>
	<detailed_description>The prognosis patient metastatic Ewing 's sarcoma family tumor ( ESF ) , rhabdomyosarcoma ( RMS ) , neuroblastoma ( NBL ) remain dismal , less 25 % long-term disease-free survival . Though less grave , prognosis cure high-risk patient approximately 50 % . New treatment strategy , include identification highly active new agent , maximize dose intensity active standard drug , development improve method consolidation eradicate microscopic residual disease , clearly need improve outcome patient . This protocol address issue commence Phase II window , high risk patient , evaluate series promise drug novel mechanism action . All patient receive 5 cycle dose-intensive `` best standard therapy '' doxorubicin ( adriamycin ) , vincristine , cyclophosphamide ( VAdriaC ) . Patients high risk relapse continue onto phase I consolidation regimen consist three cycle dose-escalated Melphalan , Ifosfamide , Mesna , Etoposide ( MIME ) . Peripheral blood stem cell transfusion ( PBSCT ) recombinant human G-CSF use supportive care measure allow maximal dose-escalation combination regimen .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Dexrazoxane</mesh_term>
	<mesh_term>Razoxane</mesh_term>
	<criteria>The patient must fall one follow diagnostic category : Ewing 's sarcoma family tumor ( ESF ) : Includes Ewing 's sarcoma ( classic , atypical , extraosseous ) , primitive sarcoma bone , ectomesenchymoma , peripheral primitive neuroectodermal tumor ( peripheral neuroepithelioma ) . Rhabdomyosarcoma : The patient must either Highrisk arm : Metastatic disease diagnosis ( site , histology ) ; OR Moderaterisk arm : Incompletely resect ( Clinical Group III ) Stage II tumor ALL stage III tumor ( regardless degree surgical resection ) . Neuroblastoma : Any patient metastatic disease diagnosis ( POG stage D Evans ' stage IV ) ; , patient locoregional metastatic disease ( POG stage C ) tumor infiltrate across midline ( Evans ' stage III ) IF elevate serum ferritin ( great 142 ng/ml ) , amplify Nmyc copy number ( great 10 copy Southern analysis ) , DNA index great 1.1 . The patient must previously treat chemotherapy radiation therapy . Patients must great equal 1 year age less equal 25 year age . Patients weight must great equal 15 kg . The patient ( his/her guardian le 18 year age ) must sign document indicate he/she aware investigational nature treatment protocol potential risk benefit may expect . Potentially fertile female patient must document negative urine serum pregnancy test . Patients must document negative HIV serologic evaluation ( Western Blot and/or ELISA ) . Patients must abnormal cardiac function ( left ventricular ejection fraction le 45 % measure gated equilibrium radionuclide angiography [ MUGA scan ] confirm echocardiography ) . Patients must impair renal function ( serum creatinine great equal twice upper limit normal age ) . Patients total bilirubin great 4.0 mg/dl ( direct bilirubin great 2.0 mg/dl ) SGOT/SGPT great five time upper limit normal ( NOT basis hepatic involvement tumor ) exclude . Patients second malignancy follow previous therapy exclude . Patients previously treat chemotherapy radiation therapy ( limited , emergency radiation therapy ) exclude . Patients HIVinfected excluced .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2002</verification_date>
	<keyword>Peripheral Stem Cell Transfusion</keyword>
	<keyword>Up-Front Phase II Window</keyword>
	<keyword>Dose-Intensive Vincristine</keyword>
	<keyword>Dose-Intensive Doxorubicin</keyword>
	<keyword>Dose-Intensive Cyclophosphamide</keyword>
	<keyword>ADR-529 Cardioprotection</keyword>
	<keyword>BID Radiation Therapy Local Control</keyword>
</DOC>